Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | USP2 | O75604 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | FGB | P02675 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551820 | 0.83 | KDM4E (0.54) | MAPTMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL5398291 | 0.81 | KDM4E (0.52) | MAPTMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL27927328 | 0.80 | MAPT (0.55) | MAPTMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL7709655 | 0.80 | TYMS (0.56) | MAPTMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL2367539 | 0.79 | MAPT (0.49) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL28678417 | 0.79 | PARP1 (0.58) | MAPTMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL2367945 | 0.79 | ALDH1A1 (0.44) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2701449 | 0.77 | ALDH1A1 (0.59) | MAPTMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL7712333 | 0.76 | KDM4E (0.62) | MAPTMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL13495347 | 0.76 | KMT2A (0.50) | MAPTMEN1KMT2AALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143449-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2012-03-27 | — | — | US | claimed |
| EP-2151429-B1 | Process for the preparation of agomelatin | SERVIER LAB (FR) | 2011-05-25 | — | — | EP | claimed |
| US-20100036163-A1 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | US | claimed |
| WO-2016046833-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-03-31 | — | — | WO | disclosed |
| WO-2014064706-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-05-01 | — | — | WO | disclosed |
| EP-2703383-A1 | Process for the preparation of agomelatine | Procos S.p.A. (IT) | 2014-03-05 | — | — | EP | disclosed |
| US-8143449-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143449-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143449-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2012-03-27 | — | — | US | disclosed |
| EP-2151429-B1 | Process for the preparation of agomelatin | SERVIER LAB (FR) | 2011-05-25 | — | — | EP | disclosed |
| JP-2010043078-A | NEW PROCESS FOR SYNTHESIS OF AGOMELATINE | LAB SERVIER | 2010-02-25 | — | — | JP | disclosed |
| WO-2010015746-A1 | NOVEL METHOD FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | WO | disclosed |
| US-20100036163-A1 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2151429-A1 | Process for the preparation of agomelatin | Les Laboratoires Servier (FR) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151429-A1 | Process for the preparation of agomelatin | Les Laboratoires Servier (FR) | 2010-02-10 | — | — | EP | disclosed |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CLEMSON UNIVERSITY | 2005-01-13 | — | — | US | disclosed |
| US-6362181-B1 | BACTERICIDES; ENZYME INHIBITORS; ANTITUMOR AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-6177423-B1 | N-(HYDROXY OR PROTECTED HYDROXY)-BENZO(DE)ISOQUINOLINE-1,3-DIONE DERIVATIVES; BACTERIAL DNA GYRASE AND DNA TOPOISOMERASE INHIBITORS USEFUL FOR ANTIBACTERIAL AGENTS HAVING REDUCED DRUG RESISTANCE AND REDUCED SIDE EFFECTS | WARNER-LAMBERT COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0939754-A2 | N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998019648-A2 | N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CNR2, CNR1, GPR68 | MAPT 2197/4885MEN1 1930/4885KMT2A 886/4885 |
| US-20100036163-A1 | Process for the synthesis of agomelatine | COMT, PNMT, TPH1 | MAPT 1010/4885MEN1 2200/4885KMT2A 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.